Results 1 to 10 of about 39,758 (253)

Correlation P2Y12 Genetic Polymorphism As Risk Factor of Clopidogrel Resistance in Indonesian Stroke Patients [PDF]

open access: goldVascular Health and Risk Management, 2023
Rakhmad Hidayat,1– 3 Al Rasyid,2,3 Salim Harris,2,3 Alida Harahap,2 Herqutanto,2 Melva Louisa,2 Erlin Listiyaningsih,4 Aldy Safruddin Rambe,5 Tonny Loho6 1Doctoral Program in Medical Sciences Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia;
Hidayat R   +8 more
doaj   +4 more sources

Increase in the risk of clopidogrel resistance and consequent TIMI flow impairment by DNA hypomethylation of CYP2C19 gene in STEMI patients undergoing primary percutaneous coronary intervention (PPCI) [PDF]

open access: goldPharmacology Research & Perspectives, 2021
Clopidogrel resistance is an important risk factor of ischemic event recurrence after optimal antiplatelet therapy. This study aims to investigate the role of CYP2C19 gene DNA methylation as one of the epigenetic factors for the risk of clopidogrel ...
Renan Sukmawan   +7 more
doaj   +3 more sources

Clopidogrel resistance and its relevance: Current concepts [PDF]

open access: yesJournal of Family Medicine and Primary Care
Clopidogrel is the most widely used P2Y12 receptor inhibitor (P2Y12i) as a part of dual antiplatelet therapy along with aspirin. Clopidogrel is a pro-drug and is metabolized to its active metabolite by the hepatic enzyme cytochrome P4502C19 (CYP2C19 ...
Akshyaya Pradhan   +3 more
doaj   +4 more sources

TMAO: a potential mediator of clopidogrel resistance [PDF]

open access: yesScientific Reports, 2021
Trimethylamine-N-oxide (TMAO) can activate platelets and increase thrombosis risk in clinical and experimental models. Meanwhile, the patients with coronary artery disease have higher serum TMAO level.
Ruisong Ma   +5 more
doaj   +5 more sources

RESISTANCE TO ANTIPLATELET DRUGS (ASPIRIN, CLOPIDOGREL) IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION

open access: diamondРациональная фармакотерапия в кардиологии, 2015
Aim. To study prevalence of resistance to acetylsalicylic acid, clopidogrel and dual resistance in percutaneous coronary intervention (PCI), to identify clinical risk factors of resistance development, to study effects of concomitant therapy on ...
V. A. Sulimov, E. V. Moroz
doaj   +5 more sources

Clopidogrel Resistance in Patients With Stroke Recurrence Under Single or Dual Antiplatelet Treatment [PDF]

open access: yesFrontiers in Neurology, 2021
Background: The factors associated with clopidogrel resistance in patients with stroke recurrence receiving single or dual antiplatelet treatment (SAPT or DAPT) may differ.
Hyun Goo Kang   +4 more
doaj   +2 more sources

Aspirin and clopidogrel resistance; a neglected gap in stroke and cardiovascular practice in Iran: a systematic review and meta-analysis [PDF]

open access: yesThrombosis Journal, 2023
Objective Antiplatelet drugs, such as Aspirin and Clopidogrel (Plavix) are effective in the primary prevention of thromboembolic events. They are commonly used to reduce the risk of recurrence of thromboembolism.
Mohammad Parsa-kondelaji   +1 more
doaj   +2 more sources

Lower Plasma miR-223 Level Is Associated with Clopidogrel Resistance in Acute Coronary Syndrome: A Systematic Review and Meta-Analysis [PDF]

open access: yesJournal of Interventional Cardiology, 2023
Objectives. To evaluate the relationship between the plasma miR-223 expression level and clopidogrel resistance in acute coronary syndrome (ACS) patients. Methods.
Hang Cheng   +9 more
doaj   +2 more sources

Clopidogrel resistance and its effect on clinical outcomes in acute coronary syndrome [PDF]

open access: yesIndian Heart Journal
Aim: The genetic polymorphism of CYP2C19 influences clopidogrel metabolism and resistance. Aim was to assess the association between CYP2C19 loss of function variation, clopidogrel resistance based on platelet reactivity units and clinical outcomes ...
Heemanshu Lodhi   +7 more
doaj   +2 more sources

The role of clopidogrel resistance-related genetic and epigenetic factors in major adverse cardiovascular events among patients with acute coronary syndrome after percutaneous coronary intervention [PDF]

open access: yesFrontiers in Cardiovascular Medicine, 2023
Despite patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and receiving clopidogrel therapy, some patients still experience major adverse cardiovascular events (MACEs).
Astuti Giantini   +13 more
doaj   +2 more sources

Home - About - Disclaimer - Privacy